Abstract

Alvotech is scheduled to report quarterly results on May 6, 2026 Post Market, with investor attention centered on revenue growth, profitability inflection potential, and the contribution from products and licensing streams as management updates its outlook for the year.

Market Forecast

Consensus drawn from the company’s latest projections points to current-quarter revenue of 140.85 million US dollars, an estimated year-over-year increase of 48.23%. Forecast EBIT is 32.34 million US dollars, implying year-over-year growth of 361.31%, while adjusted EPS is projected at approximately 0.02, up about 115.16% year over year; margin forecasts were not provided alongside these estimates.

Operationally, management’s near-term outlook suggests continued momentum from marketed biosimilars through both direct product sales and milestone-driven licensing, with mix and scale expected to be the main determinants of margin performance. Within the commercial mix, the Products segment remains the most promising growth engine, having contributed roughly 79.23 million US dollars last quarter (about 46.91% of sales), while total company revenue grew 10.14% year over year, setting a higher base for potential acceleration as newer agreements and launches progress.

Last Quarter Review

In the previous quarter, Alvotech delivered revenue of 168.90 million US dollars, gross profit margin of 63.72%, GAAP net loss attributable to the parent company of 109.00 million US dollars, a net profit margin of -64.27%, and adjusted EPS of -0.37; on a year-over-year basis, revenue increased by 10.14%, whereas adjusted EPS decreased by 54.17%.

A key financial highlight was strong gross profitability despite the bottom-line loss, reflecting favorable unit economics and pricing/mix benefits that supported a 63.72% gross margin during the quarter. From a commercial composition perspective, Products represented about 46.91% of the period’s sales (approximately 79.23 million US dollars), Licensing and Other accounted for about 52.65% (approximately 88.92 million US dollars), and Other contributed about 0.74 million US dollars; total revenue rose 10.14% year over year, demonstrating healthy top-line momentum entering the new year.

Current Quarter Outlook

Core commercial operations

The core operations—anchored by marketed biosimilars sold through a combination of direct channels and partners—are positioned to carry the topline this quarter. The prior period’s gross margin of 63.72% indicates that manufacturing scale and product mix are already supporting robust economics; sustaining or improving this trajectory depends on volume growth in key markets and a stable cost base. With last quarter’s Products sales contributing roughly 79.23 million US dollars and Licensing and Other near 88.92 million US dollars, the company is entering the quarter with balanced drivers: recurring product revenue and potential milestone/collaboration receipts. The forecast revenue of 140.85 million US dollars, paired with projected EBIT of 32.34 million US dollars, implies management is planning for a more efficient conversion of gross profit into operating income as volumes grow and operating expense intensity normalizes.

This mix has direct implications for profitability. If milestone recognition skews higher, the company could see some lumpiness in revenue and potential near-term margin volatility, yet the EBIT forecast still indicates a significant year-over-year step-up in operating leverage. Conversely, a heavier weight toward product revenue could sustain higher cash conversion over time as downstream manufacturing and distribution benefits from scale, even if specific milestones move between quarters. The pathway to a positive adjusted EPS (guided at roughly 0.02) highlights management’s confidence that operating leverage is beginning to assert itself as the year gets underway.

Most promising business

Among operating segments, Products remains the most promising growth vector this quarter. It accounted for about 46.91% of last quarter’s revenue, or approximately 79.23 million US dollars, and it benefits from ongoing uptake in launched geographies and recent partnership expansions. Recent commercialization agreements for new territories and products provide an incremental channel for volume growth, which can compound with production scale to reinforce margin gains as fixed costs are spread across more units. As a result, the company’s forecast for a 48.23% year-over-year increase in current-quarter revenue implicitly assumes a stronger contribution from Products alongside milestone timing in Licensing and Other.

The opportunity for Products this quarter is twofold: near-term sell-through in established markets and progressive onboarding of new agreements that translate into orders and shipments. If shipment timing aligns well with quarter-end cutoffs, reported revenue could skew toward the upper end of internal expectations; if not, some sales could roll forward, but the underlying demand signal remains supportive. Additionally, greater product mix skew toward higher-value biosimilars would typically support gross margin resilience near or above last quarter’s 63.72%, further bolstering EBIT relative to sales growth.

Key stock-price swing factors

The primary swing factors this quarter center on execution milestones, regulatory remediation timelines, and the speed of product ramp within partnerships. The company has disclosed receipt of complete response letters for certain candidates following facility observations and is pursuing remediation and resubmission plans; any tangible updates on inspection outcomes or resubmission timing can influence investor confidence and valuation multiples. On the commercial front, stronger-than-expected sell-through and order patterns from collaborators could raise confidence in full-year revenue pacing, particularly if sequential growth in Products outstrips the seasonally softer start that many life sciences businesses encounter in the first quarter.

Margin dynamics will be watched closely. If mix tilts toward license and milestone revenue, reported gross margin could appear elevated in the near term; if product shipments drive the beat, margin sustainability through the year may be the more constructive read-through. Investors will also scrutinize operating expenses relative to revenue growth as a gauge of cost discipline, given the significant year-over-year EBIT expansion implied by the current-quarter forecast. Finally, capital allocation and cash usage will be focal points: management has indicated confidence in funding the business with cash on hand, milestone collections, product revenue, and available financing, so clarity on cash runway and major outflows can affect sentiment around the durability of the growth plan.

Analyst Opinions

Across institutional commentary tracked in recent months, the majority view remains bullish. Among the most visible updates, a major global investment bank reiterated a Buy rating and set a 6.00 US dollars price target, stating that recent regulatory setbacks appear reflected in the share price while the commercial biosimilar portfolio continues to provide fundamental support for revenue and margin expansion. Another aggregator of analyst targets indicates the stock carries an average “overweight” stance with a mean price objective near 6.05 US dollars, consistent with a constructive bias on execution and earnings progression. Taken together, the ratio of bullish to bearish opinions in the monitored period is 100% to 0%, indicating a clear leaning toward positive expectations into the print.

The bullish case emphasizes three pillars that align with the company’s own forecasts for the quarter. First, the earnings bridge from robust gross margin into meaningfully higher EBIT suggests operating leverage is beginning to materialize as product volumes scale and fixed cost absorption improves. The projected 361.31% year-over-year increase in EBIT to 32.34 million US dollars underscores this thesis, while the move to a small positive adjusted EPS near 0.02 offers a milestone for investor narratives around a profitability inflection. Second, revenue visibility is improving through a combination of recurring product sales and milestone flows from development and commercialization agreements, which supports the 48.23% year-over-year revenue growth forecast to 140.85 million US dollars. Analysts argue that this dual-engine model can smooth out quarter-to-quarter variability over time, even if individual milestones cause intermittent lumpiness.

Third, while regulatory items have created uncertainty, analysts in the majority view believe remediation steps and resubmission plans are advancing and are increasingly reflected in valuation. Positive interim developments—such as new commercialization pacts for select markets and top-line clinical readouts—are highlighted as indicators that the medium-term launch cadence remains intact. As these programs progress toward potential approvals and commercial entry points, analysts expect additional revenue layers late in the year and into next year, with the Products segment positioned to benefit most from that ramp.

From a near-term trading perspective, the majority view frames the May 6, 2026 Post Market report as a catalyst more for guidance color and qualitative updates than for one-off upside surprises. The consensus already embeds a solid step-up in year-over-year growth metrics; upside could come from stronger-than-expected product shipment timing and more favorable mix, while downside would be more likely if milestone recognition is deferred and product shipments slide into the subsequent quarter. On balance, analysts in the bullish camp expect management to deliver a constructive update on both revenue trajectory and the roadmap for addressing regulatory items, which would support the case for revenue and EBIT outperformance later in the year.

In summary, the prevailing institutional stance is that Alvotech’s path toward higher operating leverage and a sustainable earnings profile is becoming clearer. The company’s last quarter performance—168.90 million US dollars in revenue at a 63.72% gross margin, with Products at roughly 79.23 million US dollars and Licensing and Other at about 88.92 million US dollars—provides a base from which stronger contribution is expected. With current-quarter projections calling for 140.85 million US dollars in revenue, 32.34 million US dollars in EBIT, and an adjusted EPS turning positive to approximately 0.02, bullish analysts see a favorable setup into the release and anticipate that management’s commentary will reinforce confidence in mid-year and second-half acceleration.